All News

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Consulting with some pharmacist moms and colleagues, these are the top tips for how they make the holidays more of a celebration and less of a logistical nightmare.

Top news of the day from across the health care landscape.

A patient at age 65 with high blood pressure could extend their life by more than a year with intensive treatment focused on a target systolic blood pressure of less than 120 mm Hg.

The FDA has approved cenobamate tablets (XCOPRI, SK Life Sciences) for treatment of partial-onset seizures in adults.

Under a new international collaboration, the FDA has granted supplemental approval to acalabrutinib (Calquence, AstraZeneca) for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic leukemia.

Tafenoquine’s approval was the culmination of years of scientific discovery and research by experts in the field of Malariology and Infectious Disease, involving over 25 clinical trials and over 3000 participants.

A team of researchers from Columbia University, New York City compared the incidence of chlamydia infection in adolescent LARC users to non-LARC users.

The 48-week phase 4 study showed that tocilizumab was more effective than rituximab in patients with rheumatoid arthritis with low B cell levels in synovial tissue.

The Clinical Performance and Quality Measures included 6 performance measures, 6 process quality measures, and a new category of 10 structural quality measures for adults with high blood pressure.

Top news of the day from across the health care landscape.

Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss the benefits of attending NASP during the NASP Annual Meeting in Washington, DC.

Certain subgroups may see a greater reduction in heart failure hospitalizations and cardiovascular death with the combination of sacubitril and valsartan.

The FDA has granted approvel to Alnylam’s givosiran (Givlaari) for the treatment of adults with acute hepatic porphyria.

Durvalumab (Imfinzi, AstraZeneca) and tremelimumab plus chemotherapy improved progression-free survival in first-line stage 4 non-small cell lung cancer.

A study published in the Clinical Journal of American Society of Nephrology found that a healthy dietary pattern may prevent chronic kidney disease (CKD) and albuminuria.

Top news of the day from across the health care landscape.

The Community Pharmacy Foundation recently sponsored a study entitled, “Evaluation Of Enhanced Community Pharmacy Services.”

A recent study suggests that hyperkalemia and uncomplicated hyperglycemia in patients treated in the emergency department is commonly caused by iatrogenesis.

FDA draft guidance allows for an animal drug to be compounded from bulk drug substances in limited circumstances for which there is no FDA-approved treatment.